Breast-conserving treatment for ductal carcinoma in situ: Impact of boost and tamoxifen on local recurrences.

CONCLUSIONS: This study confirms the ductal carcinoma in situ treatment heterogeneity among countries and the unfavourable prognostic role of nuclear grade. Tamoxifen reduces local recurrence rates and might be considered for some subgroups of patients, but further confirmation is required. The boost usefulness still remains unclear. PMID: 27344537 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27344537?dopt=Abstract

Source: Cancer Radiotherapie - June 21, 2016 Category: Cancer & Oncology Authors: Cutuli B, Wiezzane N, Palumbo I, Barbieri P, Guenzi M, Huscher A, Borghesi S, Delva C, Iannone T, Vianello E, Rosetto ME, Aristei C Tags: Cancer Radiother Source Type: research